The Part 11 Controversy: A Root Cause Analysis and Science-Based Solutions

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-06-01-2005
Volume 205 Supplement
Issue 3

The confusion surrounding the application of 21 CFR Part 11 can be solved by focusing on the common rationale that both protects the public health and drives the fundamental basis of the industry's business: good science.

Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content